Premier Polyfilm standalone net profit declines 16.57% in the March 2025 quarter
Net profit of Premier Polyfilm declined 16.57% to Rs 5.59 crore in the quarter ended March 2025 as against Rs 6.70 crore during the previous quarter ended March 2024. Sales rose 4.88% to Rs 72.18 crore in the quarter ended March 2025 as against Rs 68.82 crore during the previous quarter ended March 2024.
For the full year,net profit rose 26.21% to Rs 26.00 crore in the year ended March 2025 as against Rs 20.60 crore during the previous year ended March 2024. Sales rose 1.55% to Rs 264.12 crore in the year ended March 2025 as against Rs 260.09 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 72.1868.82 5 264.12260.09 2 OPM % 12.4114.92 - 15.4713.25 - PBDT 8.689.95 -13 39.7032.43 22 PBT 7.398.67 -15 34.6327.27 27 NP 5.596.70 -17 26.0020.60 26
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
23 minutes ago
- Time of India
IndusInd Bank to raise Rs 30,000 crore through equity and debt instruments
Synopsis IndusInd Bank's board has approved raising up to Rs 30,000 crore through equity and debt instruments. The RBI has allowed the Hinduja Group, the bank's promoter, to nominate two directors to the board. This decision follows a period of crisis for the bank, marked by accounting anomalies and a CEO exit.
The Hindu
23 minutes ago
- The Hindu
Natco Pharma to acquire stake in South African firm Adcock Ingram for ₹2,000 crore
Natco Pharma has made an offer to acquire nearly 36% stake in South African pharmaceutical company Adcock Ingram Holdings (AIHL) for $226 million (around ₹2,000 crore). The proposal to acquire the stake from minority shareholders in an all cash deal is a strategic investment aimed at to expanding geographic footprint in South Africa, Natco said on Wednesday. Founded in 1890, AIHL has a diverse product portfolio, from generic and branded formulations, critical-care hospital products to consumer and home-care products. It operates across four segments -prescription, consumer, OTC and hospitals. The acquisition is expected to be completed by 2025. Post-acquisition, AIHL will continue to operate as a private South African business with Bidvest holding 64.25% and Natco 35.75%, including a prior held 0.80% stake, in the company. Post-transaction, Natco will consolidate 35.75% of AIHL net profits in its financial results. AIHL clocked revenue of $536 million in the financial year June 2024 and profit after tax of $45 million. 'Adcock Ingram is a respectable pharmaceutical company with well-recognised brands and products and maintains a leading position in the South African pharmaceutical market. The proposed transaction will provide Natco Pharma with a well-established entry into the Southern African market. It will also allow us to tap into new revenue streams and expand our footprint in one of the largest and growing emerging markets, while providing a gateway to the African continent,' CEO and Vice-Chairman Rajeev Nannapaneni said. Besides the acquisition, Natco Pharma Board also approved a proposal to incorporate a wholly owned subsidiary in South Africa with an investment of up to Rs.2,100 crore by this year to enter new geographies for growth and increased profitability. It also approved a proposal to liquidate wholly owned subsidiary Time Cap Overseas (TCOL), and directly hold the investment in step down subsidiary NatcoFarma do Brasil. Natco shares closed 2.01% higher at ₹1,034.75 apiece on the BSE.
India.com
23 minutes ago
- India.com
Good news for Narayana Murthy, Infosys earns Rs 69210000000 in…, CEO Salil Parekh says…
Narayana Murthy (File) Infosys Ltd on Wednesday reported an 8.7% year-on-year increase in net profit for the June quarter, while also narrowing its full-year revenue guidance following better-than-expected earnings growth. The IT major posted a consolidated net profit of Rs 6,921 crore for the April–June quarter of FY2025-26, up from Rs 6,368 crore in the corresponding period last year, the company said in a statement. Infosys Q1 Results The IT services company narrowed its annual revenue growth forecast to 1 per cent to 3 per cent band from a prior 0-3 per cent range. Revenue from operations at Rs 42,279 crore was 7.53 per cent higher year-on-year and 3.3 per cent quarter-on-quarter, on the back of strong performance in AI and deal wins. Net profit however fell 1.5 per cent sequentially when compared with the January-March quarter. 'Our performance in Q1 demonstrates the strength of our enterprise AI capabilities, the success in client consolidation decisions, and the dedication of our over 300,000 employees. Our large deal wins of USD 3.8 billion reflect our distinct competitive positioning and deep client relationships,' Infosys CEO and MD Salil Parekh said. Infosys CEO Salil Parekh On Q1 Results Briefing media at the Q1 earnings call, Parekh noted that the start to financial year had been strong. 'The main drivers of our growth were a leadership in enterprise AI, and a continued success in clients selecting us for consolidations. We are seeing good demand for AI agents,' he said. Geographically, North America accounted for 56.5 per cent of quarterly revenue, down from 58.9 per cent in the corresponding period of the previous fiscal. Europe increased its share to 31.5 per cent, up from 28.4 per cent in the Q1 FY25. Infosys CFO Jayesh Sanghrajka said that Europe has been strong footing for the company for past many quarters. 'That's on the back of the investment that we made a few years back in Europe. We had identified Europe as a geography to invest into and all of that is working well across sectors….but still, US remains the largest geography for us,' Sanghrajka said. The Large Deal TCV (or total contract value) stood at USD 3.8 billion.
